FDA rejects ITM radiopharma therapy while WHO defends immunization schedules

The U.S. Food and Drug Administration has issued a rejection of a radiopharmaceutical therapy identified as ITM, indicating that the product did not meet the agency's requirements for approval.

The decision halts the therapy's progression toward market entry and signals that further data or modifications will be needed before reconsideration.

In a separate regulatory development, the World Health Organization has publicly defended its current immunization schedules, emphasizing their scientific basis and continued relevance.